Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Schizophrenia

Free Subscription Articles published in Psychiatry Res Retrieve available abstracts of 313 articles: HTML format

Single Articles

July 2026
1. ZHANG Y, Liu Y, Wang X, Zhu Y, et al
   The impact of sleep and physical activity on the quality of life of community-dwelling Schizophrenia patients: a cross-sectional study.
   Psychiatry Res. 2026;364:117312.
   PubMed     Abstract available
   
   
   
2. SONG X, Feng T, Lin H, Qian H, et al
   A real-world pharmacovigilance study of Xanomeline-Trospium events in the FDA adverse event reporting system (FAERS).
   Psychiatry Res. 2026;361:117162.
   PubMed     Abstract available
   
   
   
3. HUBBARD LA, Zhang JN, Moore RC, Depp CA, et al
   Does hearing voices make you nervous? An ecological momentary assessment investigation of momentary emotional responses to the occurrence of psychotic symptoms.
   Psychiatry Res. 2026;361:117098.
   PubMed     Abstract available
   
   
   June 2026
4. ZHANG X, Li X, Zhang G, Li C, et al
   Association between serum uric acid levels and cognitive performance in first-episode drug-naive schizophrenia: A large cross-sectional study.
   Psychiatry Res. 2026;364:117314.
   PubMed     Abstract available
   
   
   
5. MIYAKE R, Esaki Y, Taniguchi R, Obayashi K, et al
   Light exposure at night and subjective and objective sleep parameters in patients with schizophrenia: A cross-sectional analysis of the LENS study.
   Psychiatry Res. 2026;364:117302.
   PubMed     Abstract available
   
   
   
6. SOLBERG AC, Ottesen AA, Barrett EA, Mork E, et al
   Characteristics of self-harm in patients with first episode psychosis.
   Psychiatry Res. 2026;364:117278.
   PubMed     Abstract available
   
   
   
7. MOREJON AJV, Reyes AV, Munoz-Caracuel MA, Vazquez-Morejon R, et al
   Predicting relapse risk from patients' perceptions of family functioning in early psychosis: A three-year longitudinal study.
   Psychiatry Res. 2026;364:117281.
   PubMed     Abstract available
   
   
   
8. IFTENI P, Miron AA, Necula R, Dima L, et al
   Patterns of onset and progression of psychoses induced by psychoactive substance use.
   Psychiatry Res. 2026;364:117283.
   PubMed     Abstract available
   
   
   
9. KROKEN RA, Johnsen E, Alisauskiene R, Anda LG, et al
   Cytokine changes during a 12-month pragmatic randomized trial in schizophrenia spectrum disorders comparing amisulpride, aripiprazole and olanzapine.
   Psychiatry Res. 2026;364:117266.
   PubMed     Abstract available
   
   
   
10. ZENG Y, Wang X, Wu H, Tan X, et al
    Post-marketing safety surveillance of the novel muscarinic antipsychotic Xanomeline-Trospium for schizophrenia: A comparative disproportionality analysis against olanzapine based on FAERS data.
    Psychiatry Res. 2026;364:117270.
    PubMed     Abstract available
    
    
    
11. YILDIZ FBP, Calis AK, Dokuz G, Kilicarslan T, et al
    Choroidal vascularity index in schizophrenia and bipolar disorder.
    Psychiatry Res. 2026;364:117268.
    PubMed     Abstract available
    
    
    
12. OKA S, Yamazaki T, Takefuji Y
    Breaking the spline: Why distributed lag non-linear models miss thresholds in environmental psychiatry.
    Psychiatry Res. 2026;360:117104.
    PubMed     Abstract available
    
    
    
13. XIAO D, Zhu C
    The role of serum BDNF levels in cognitive dysfunction among psychiatric disorders.
    Psychiatry Res. 2026;360:117069.
    PubMed     Abstract available
    
    
    May 2026
14. ZHANG K, Xue H, Wang C, Li N, et al
    Adjunctive intermittent theta-burst stimulation for first-episode schizophrenia: A randomized clinical trial.
    Psychiatry Res. 2026;364:117247.
    PubMed     Abstract available
    
    
    
15. KHAKI M, Massoudifar A, Davoodian N, Mousavi P, et al
    Investigation of potential associations between four redox-related long non-coding RNAs and glutathione peroxidase in schizophrenia: a combination of bioinformatics and experimental analyses.
    Psychiatry Res. 2026;364:117241.
    PubMed     Abstract available
    
    
    
16. RICCI V, Paggi A, Martinotti G, Maina G, et al
    Functional recovery trajectories in cannabis-induced first-episode psychosis: The role of dissociative symptoms in the discrepancy between symptomatic improvement and functional outcomes.
    Psychiatry Res. 2026;363:117240.
    PubMed     Abstract available
    
    
    
17. YANG Y, Zhu Y, Wu R, Jiang F, et al
    Short-term development of neurocognition in early-stage schizophrenia with predominant negative symptoms.
    Psychiatry Res. 2026;363:117230.
    PubMed     Abstract available
    
    
    
18. WU G, Shen M, Lin Y, Chen H, et al
    Effects of fronto-occipital transcranial alternating current stimulation for treating schizophrenia with prominent negative symptoms: A double-blind, randomized, sham-controlled trial.
    Psychiatry Res. 2026;362:117216.
    PubMed     Abstract available
    
    
    
19. BOZDAG MC, Kumcu A, Senel LK, Temizkan HN, et al
    Spoken language biomarkers in Turkish-speaking schizophrenia patients: Evidence from linguistic analysis and word embeddings.
    Psychiatry Res. 2026;362:117215.
    PubMed     Abstract available
    
    
    
20. SAGUES T, Ferrer A, Delgado JF, Julia G, et al
    Clozapine use and COVID-19 risk: A systematic review, meta-analysis, and retrospective cohort evidence.
    Psychiatry Res. 2026;359:117040.
    PubMed     Abstract available
    
    
    
21. DE LAS CUEVAS C, Sanz EJ, de Leon J
    A study in VigiBase of clozapine fatal outcomes in 7874 middle-aged versus 4380 young adults.
    Psychiatry Res. 2026;359:117037.
    PubMed     Abstract available
    
    
    April 2026
22. CHEN W, Xu C, Deng W, Liang J, et al
    Impact of second-generation antipsychotics on white matter microstructure in schizophrenia: A DTI study.
    Psychiatry Res. 2026;362:117182.
    PubMed     Abstract available
    
    
    
23. AHMAD I, Wang Y, Guo S, Cui L, et al
    Exploring schizophrenia-associated image-derived digital phenotypes in dual-energy X-ray densitometer scans of non-dominant distal forearm: An explainable machine-learning framework.
    Psychiatry Res. 2026;362:117186.
    PubMed     Abstract available
    
    
    
24. RAMOS MA, Hernandez C, Arranz B
    Iron dysregulation across the schizophrenia lifespan: A systematic review from prenatal risk to postmortem findings.
    Psychiatry Res. 2026;362:117193.
    PubMed     Abstract available
    
    
    
25. KOC I, Koc EA
    The effects of physical exercise on simple inflammatory markers, systemic immune inflammation index, and systemic immune response index in patients with schizophrenia.
    Psychiatry Res. 2026;362:117187.
    PubMed     Abstract available
    
    
    
26. HU G, Wei D, Zhang J, Liu J, et al
    Corrigendum to "Effect of computerized cognitive remediation therapy combined with individualized occupational therapy on cognitive function and functional outcomes in patients with schizophrenia: A randomized controlled trial" [Psychiatry Research 35
    Psychiatry Res. 2026 Apr 20:117166. doi: 10.1016/j.psychres.2026.117166.
    PubMed    
    
    
    
27. LEBOVITZ JG, Kittleson AR, Sloan AF, Torregrossa LJ, et al
    Longitudinal relationships among dissociation, paranoia, and anxiety in a clinical sample of individuals with schizophrenia-spectrum conditions.
    Psychiatry Res. 2026;362:117174.
    PubMed     Abstract available
    
    
    
28. HIRA S, Ozcan O, Ipcioglu OM, Hatipoglu M, et al
    Impaired central methylation capacity in drug-naive first-episode psychosis: Evidence from cerebrospinal fluid one-carbon metabolism.
    Psychiatry Res. 2026;361:117169.
    PubMed     Abstract available
    
    
    
29. KIM KH, Kim C, Song I, Kim DS, et al
    Nationwide trends in antipsychotic and co-medication prescribing for schizophrenia: analysis of National Health Insurance data (2011-2023).
    Psychiatry Res. 2026;361:117159.
    PubMed     Abstract available
    
    
    
30. DUDAKLI BB, Uzel HK, Ocak MS, Esen Oksuzoglu M, et al
    Changes in serum Nogo-A and BDNF levels following treatment in drug-naive first-episode schizophrenia: A naturalistic prospective study.
    Psychiatry Res. 2026;361:117149.
    PubMed     Abstract available
    
    
    
31. DOHERTY E, Laighneach A, Casburn M, Quilligan F, et al
    Genetic studies of psychosocial disability establish correlations and causal relationships with neuropsychiatric disorders.
    Psychiatry Res. 2026;358:116963.
    PubMed     Abstract available
    
    
    March 2026
32. DANIEL DTG, Choi JJ, Aluri J, McCaulley C, et al
    Qualitative analysis of long-term clozapine adherence in schizophrenia: An exploratory study.
    Psychiatry Res. 2026;361:117136.
    PubMed     Abstract available
    
    
    
33. TANG W, Guan C, Ling Z, Zhang X, et al
    Development of a risk prediction model for relapse in patients with schizophrenia based on a systematic review and meta-analysis.
    Psychiatry Res. 2026;361:117106.
    PubMed     Abstract available
    
    
    
34. SEDEF MM, Oruc EB, Bulut SD, Hatil SI, et al
    Zonulin as an endophenotype for schizophrenia: A study in patients and unaffected siblings.
    Psychiatry Res. 2026;360:117102.
    PubMed     Abstract available
    
    
    
35. CORRELL CU, Yildirim M, Zhang Z, Palma AM, et al
    Efficacy and safety of brexpiprazole in early-episode schizophrenia: post hoc analysis of Phase 3 clinical trials in adults and adolescents.
    Psychiatry Res. 2026;360:117091.
    PubMed     Abstract available
    
    
    
36. LUTHER L, Barolette JT, Patron C, Howell E, et al
    Discrepancies between ideal and actual affect predict negative symptoms in schizophrenia in daily life: An ecological momentary assessment study.
    Psychiatry Res. 2026;360:117087.
    PubMed     Abstract available
    
    
    
37. LI Y, Ding X
    Letter to editor regarding "Cognition in schizophrenia across phases of illness: A systematic review and meta-analysis".
    Psychiatry Res. 2026;360:117094.
    PubMed    
    
    
    
38. GOH KK, Chen PY, Chang HM, Kanahara N, et al
    Longitudinal associations among childhood trauma, oxytocin, and metabolic risk in schizophrenia.
    Psychiatry Res. 2026;360:117088.
    PubMed     Abstract available
    
    
    
39. MOU L, Gong B, Tan Q, Wang H, et al
    Classification of functional near-infrared spectroscopy (fNIRS) signals in schizophrenia and bipolar disorder using deep learning methods.
    Psychiatry Res. 2026;360:117084.
    PubMed     Abstract available
    
    
    February 2026
40. PENG G, Xiang A, Tang W
    Comment on: "Levels of and changes in psychosis symptoms and clinical insight: Exploring the impact of differential antipsychotic mechanisms"-From acknowledging attrition to quantifying its potential bias.
    Psychiatry Res. 2026;360:117060.
    PubMed    
    
    
    
41. LI YW, Yeh TC, Chien WC, Chung CH, et al
    Role of depression and anxiety in the treatment modalities and age-stratified dementia risk in patients with schizophrenia, a real-world nationwide cohort study.
    Psychiatry Res. 2026;360:117061.
    PubMed     Abstract available
    
    
    
42. BRENUGAT L, Mendy M, Maitre A, Danset C, et al
    Personalized approach to cognitive remediation for people with schizophrenia and autism.
    Psychiatry Res. 2026;359:117054.
    PubMed     Abstract available
    
    
    
43. SHIZUKAWA K
    Letter to the Editor: Comment regarding "A comparative study of medication adherence in schizophrenia patients receiving clozapine and other antipsychotics".
    Psychiatry Res. 2026;359:117047.
    PubMed    
    
    
    
44. FUKUMOTO K, Ohi K, Ito S, Yasuda Y, et al
    Psychiatrists' adherence to guideline-recommended pharmacotherapy for schizophrenia affects subcortical structural alterations in the brains of patients with schizophrenia.
    Psychiatry Res. 2026;359:117050.
    PubMed     Abstract available
    
    
    
45. TESSIER A, Fatseas M, Dansou Y, Godin O, et al
    Tobacco craving and suicidal risk in a cohort of subjects with schizophrenia: results from the national FACE-SZ cohort.
    Psychiatry Res. 2026;359:117028.
    PubMed     Abstract available
    
    
    
46. ZHANG HM, Zhang YH
    Letter to the Editor regarding "Social networks and symptomatology in recently hospitalized individuals with schizophrenia-spectrum disorders: A six-month longitudinal study".
    Psychiatry Res. 2026;359:116997.
    PubMed    
    
    
    
47. OSTERGAARD SD, Speed M, Hall ASM, Agerbo E, et al
    Genetic liability to mental disorders and being delivered via cesarean section.
    Psychiatry Res. 2026;356:116871.
    PubMed     Abstract available
    
    
    
48. REDLICH BOSSY M, Muller DR, Cecere G, Vetter S, et al
    Feasibility and efficacy of short cognitive remediation interventions for schizophrenia: a randomized active control trial.
    Psychiatry Res. 2026;356:116881.
    PubMed     Abstract available
    
    
    
49. SANTANGELO G, Gnazzo M, Baldini V, De Ronchi D, et al
    Unraveling the gender divide: A systematic review of gender-specific differences at the first episode of psychosis.
    Psychiatry Res. 2026;356:116914.
    PubMed     Abstract available
    
    
    
50. GARCIA-JIMENEZ J, Lafuente-Casanova O, Salas R, Rodriguez C, et al
    12-Month mirror study on the effectiveness and safety of six-month paliperidone palmitate in patients with schizophrenia: A Multicenter Andalusian Cohort (PAPSEM study).
    Psychiatry Res. 2026;356:116903.
    PubMed     Abstract available
    
    
    
51. SWIECZKOWSKI D, Kwasny A, Cubala WJ
    Cross-sectional analysis of ongoing clinical trials involving lamotrigine for mental disorders: Insights from ClinicalTrials.gov and the EU clinical trials.
    Psychiatry Res. 2026;356:116878.
    PubMed     Abstract available
    
    
    
52. BROWN WJ, Graziano RC, Babb ZA, Zampogna AM, et al
    Modeling the symptom connections between posttraumatic stress disorder and comorbid severe mental illness.
    Psychiatry Res. 2026;356:116861.
    PubMed     Abstract available
    
    
    January 2026
53. LEE T, Choi BS, Kim JH
    Cumulative incidence of schizophrenia-spectrum disorders in children and adolescents with neurodevelopmental disorders: A retrospective cohort study.
    Psychiatry Res. 2026;358:116981.
    PubMed     Abstract available
    
    
    
54. MUSTONEN A, Niemela S, Denissoff A, Forti MD, et al
    Optimizing antipsychotic dosing for relapse prevention in cannabis-induced psychosis: A nationwide cohort study.
    Psychiatry Res. 2026;358:116966.
    PubMed     Abstract available
    
    
    
55. VERIM B, Demirlek C, Zorlu N, Erdeniz B, et al
    Transdiagnostic investigation of white matter integrity and cortical thickness in cognitive subgroups within the schizophrenia-bipolar spectrum.
    Psychiatry Res. 2026;358:116964.
    PubMed     Abstract available
    
    
    
56. SCHOCK GV, Kittleson AR, Halverson AS, Liu J, et al
    Social networks and symptomatology in recently hospitalized individuals with schizophrenia-spectrum disorders: A six-month longitudinal study.
    Psychiatry Res. 2026;358:116960.
    PubMed     Abstract available
    
    
    
57. LIN CH, Chiang CL, Yu DY, Horio H, et al
    Clinical remission, functional recovery, and employment in early-phase schizophrenia treated with paliperidone palmitate: An 18-month longitudinal Asia-Pacific study.
    Psychiatry Res. 2026;358:116955.
    PubMed     Abstract available
    
    
    
58. ASENJO-LOBOS C, Arancibia M, Cortes-Jofre M, Huang T, et al
    Comparative efficacy and safety of clozapine and olanzapine in schizophrenia and related disorders: An updated systematic review.
    Psychiatry Res. 2026;358:116956.
    PubMed     Abstract available
    
    
    
59. STABELL LA, Johnsen E, Kroken R, Loberg EM, et al
    Levels of and changes in psychosis symptoms and clinical insight: Exploring the impact of differential antipsychotic mechanisms.
    Psychiatry Res. 2026;358:116948.
    PubMed     Abstract available
    
    
    
60. VAN BUITENEN N, van den Berg C, Meijers J, Harte J, et al
    Prevalence and patterns of comorbid mental disorders in a male forensic psychiatric sample: A network analysis.
    Psychiatry Res. 2026;355:116847.
    PubMed     Abstract available
    
    
    
61. GRAUX J, Thillay A, Sommer J, Morel-Kohlmeyer S, et al
    The ANCog: A French self-report scale for assessing subjective cognitive complaints in rehabilitation samples.
    Psychiatry Res. 2026;355:116830.
    PubMed     Abstract available
    
    
    December 2025
62. GRECA E, Belalcazar-Vivas V, Ferrer GF, Michel JJ, et al
    SHAPING MINDS: A systematic review and meta-analysis on the effects of structured exercise in schizophrenia spectrum disorders.
    Psychiatry Res. 2025;357:116919.
    PubMed     Abstract available
    
    
    
63. HUANG J, Xu J, Zhao Y, Zhang M, et al
    Analysis of language patterns in schizophrenia based on natural language processing.
    Psychiatry Res. 2025;356:116894.
    PubMed     Abstract available
    
    
    
64. SMIECINSKA J, Sakson-Obada O
    Linguistic prosody perception in schizophrenia patients.
    Psychiatry Res. 2025;356:116899.
    PubMed     Abstract available
    
    
    
65. LIANG M, Wang J, Zhao W
    Effectiveness of visual-based interventions for ameliorating theory of mind-related impairments in patients with schizophrenia: A systematic review and meta-analysis.
    Psychiatry Res. 2025;356:116891.
    PubMed     Abstract available
    
    
    
66. CHANALIA S, Grover S, Chakrabarti S
    A comparative study of medication adherence in schizophrenia patients receiving clozapine and other antipsychotics.
    Psychiatry Res. 2025;358:116879.
    PubMed     Abstract available
    
    
    
67. PUZIA M, Stokes B, Oh HY, Anglin DM, et al
    Reasons for discrimination and mental health symptoms among ethnoracially diverse individuals in the early stages of psychosis.
    Psychiatry Res. 2025;356:116869.
    PubMed     Abstract available
    
    
    
68. BERTRAND CE, Pokorny V, Foti D, Osborne KJ, et al
    Neural correlates of conversational turn-taking perception in individuals at clinical high-risk for psychosis.
    Psychiatry Res. 2025;356:116870.
    PubMed     Abstract available
    
    
    
69. DIELEMANS DAM, Hagen JM, Sutterland AL, Bourgonje AR, et al
    Systemic inflammatory and oxidative stress alterations in recent-onset psychosis: findings from a non-smoking case-control sample.
    Psychiatry Res. 2025;356:116866.
    PubMed     Abstract available
    
    
    November 2025
70. CHEN H, Li J, Jia X, Wang X, et al
    Efficacy of high-frequency transcranial magnetic stimulation to improve negative symptoms in patients with Schizophrenia: A meta-analysis of randomized controlled trials.
    Psychiatry Res. 2025;356:116868.
    PubMed     Abstract available
    
    
    
71. HOWIE JH, Fielden CR, Rempfer MV
    Cognition in schizophrenia across phases of illness: A systematic review and meta-analysis.
    Psychiatry Res. 2025;355:116856.
    PubMed     Abstract available
    
    
    
72. OSTOJIC D, Quilligan F, Cannon DM, Madden MG, et al
    Machine learning identifies traumatic experiences as being associated with auditory verbal hallucinations in both a non-clinical population and individuals diagnosed with psychosis.
    Psychiatry Res. 2025;356:116854.
    PubMed     Abstract available
    
    
    
73. SAKA IM, Arslan FC, Demir S, Mentese A, et al
    The relationship between serum Interleukin- 6, Interleukin- 18, Interleukin- 2, Eotaxin-1, Monocyte Chemoattractant Protein 1 levels and cognitive functions in treatment-resistant schizophrenia.
    Psychiatry Res. 2025;355:116835.
    PubMed     Abstract available
    
    
    
74. SUN A, Eakins RE, Gozlan EC, Chobrutskiy A, et al
    A quantitative assessment of TRB CDR3-CMV antigen chemical interactions distinguishes schizophrenia patients in case/control comparisons.
    Psychiatry Res. 2025;355:116834.
    PubMed     Abstract available
    
    
    
75. MIZUTANI R, Saiga R, Yamamoto Y, Inomoto C, et al
    Pyramidal soma size in the anterior cingulate cortex is small in schizophrenia and correlates with hallucination score.
    Psychiatry Res. 2025;355:116822.
    PubMed     Abstract available
    
    
    
76. CELIC RUZIC M, Zarkovic N, Rossini Gajsak L, Filipcic I, et al
    Persistent oxidative stress and functional outcomes in early psychosis: A longitudinal study.
    Psychiatry Res. 2025;354:116818.
    PubMed     Abstract available
    
    
    
77. NADER G, Ducharme M, Torres-Carmona E, Fischer C, et al
    A novel method of measuring cortical thickness in schizophrenia spectrum disorders: a preliminary analysis of multi-echo fast spoiled gradient echo MRI.
    Psychiatry Res. 2025;356:116817.
    PubMed     Abstract available
    
    
    October 2025
78. GUO X, Wu S, Jia T, Sun Z, et al
    Plasma fatty acids levels and risk of schizophrenia in the UK Biobank: a prospective cohort study.
    Psychiatry Res. 2025;354:116805.
    PubMed     Abstract available
    
    
    
79. VERDAGUER-RODRIGUEZ M, Lopez-Carrilero R, Diaz-Cutraro L, Ferrer-Quintero M, et al
    Sex-based differences in neurocognitive functioning in first-episode psychosis: An exploratory analysis.
    Psychiatry Res. 2025;354:116803.
    PubMed     Abstract available
    
    
    
80. DELISI LE
    Reflections from half a century of progress searching for the causes of schizophrenia: Stanley Dean award presentation 2025.
    Psychiatry Res. 2025;354:116790.
    PubMed     Abstract available
    
    
    
81. HU G, Wei D, Zhang J, Liu J, et al
    Effect of computerized cognitive remediation therapy combined with individualized occupational therapy on cognitive function and functional outcomes in patients with schizophrenia: A randomized controlled trial.
    Psychiatry Res. 2025;354:116789.
    PubMed     Abstract available
    
    
    
82. ZENCIR T, Celik Zencir A, Tekinarslan G, Koc M, et al
    The role of socioeconomic and structural vulnerability risk factors in employment outcomes for individuals with Schizophrenia and other psychotic disorders.
    Psychiatry Res. 2025;354:116782.
    PubMed     Abstract available
    
    
    
83. LEIJALA J, Kampman O, Gunnar T, Suvisaari J, et al
    Treatment adherence in first-episode psychosis: A one-year follow-up study comparing self-reported adherence, pharmacy refill data, and therapeutic drug monitoring.
    Psychiatry Res. 2025;354:116780.
    PubMed     Abstract available
    
    
    
84. MUELLER N, Mulfarth R, Seuffert S, Dannlowski U, et al
    Figurative language production in schizophrenia, bipolar disorder, and depression.
    Psychiatry Res. 2025;354:116772.
    PubMed     Abstract available
    
    
    
85. ASENJO-LOBOS C, Arancibia M, Garcia-Ribera C, Cortes-Jofre M, et al
    Comparative efficacy and safety of Clozapine vs. Quetiapine in schizophrenia and related disorders: An updated systematic review.
    Psychiatry Res. 2025;353:116764.
    PubMed     Abstract available
    
    
    
86. PREOBRAZENSKI N, Hsieh T, Robertson C, Thai H, et al
    Polypharmacy in clozapine-treated patients: A retrospective analysis of 667 patients in Ottawa, Canada.
    Psychiatry Res. 2025;352:116684.
    PubMed     Abstract available
    
    
    
87. XUE J, Zhai Z, Li X, Zhu Y, et al
    Deep transcranial magnetic stimulation over the anterior cingulate cortex in treatment-resistant schizophrenia: A pilot double-blind, randomized controlled trial.
    Psychiatry Res. 2025;353:116756.
    PubMed     Abstract available
    
    
    September 2025
88. PANGANIBAN KJ, Smith ECC, Stogios N, Agarwal SM, et al
    The cognitive metabolomic signatures in schizophrenia spectrum disorders: A systematic review.
    Psychiatry Res. 2025;353:116742.
    PubMed     Abstract available
    
    
    
89. MONTI P, Iodice S, Capuzzi E, Borroni E, et al
    Short-term exposure to particulate matter and apparent temperature is associated with schizophrenia severity in Italy.
    Psychiatry Res. 2025;353:116735.
    PubMed     Abstract available
    
    
    
90. SOTERO-MORENO A, Guardiola-Ripoll M, Hostalet N, Moreira M, et al
    Effects of DISC1 and hypoxia-sensitive genes on dermatoglyphics and cognitive function in schizophrenia.
    Psychiatry Res. 2025;353:116721.
    PubMed     Abstract available
    
    
    
91. BIAGETTI R, Caiazza L, Giuva T, Pirani G, et al
    Clozapine-induced cardiac toxicity and successful rechallenge in children and adolescents: a systematic review and new case report.
    Psychiatry Res. 2025;351:116646.
    PubMed     Abstract available
    
    
    
92. GOMBAS SA, Moran EK, Barch DM
    Relationships between cognition and symptoms across mood and psychotic disorders.
    Psychiatry Res. 2025;351:116628.
    PubMed     Abstract available
    
    
    
93. ZHU T, Jiao X, Zhou J, Nicholas PJ, et al
    Efficacy of rTMS on SCZ symptoms: Insights from connectome mapping.
    Psychiatry Res. 2025;351:116568.
    PubMed     Abstract available
    
    
    
94. LU N, Wang M, Zheng Z, Zhang F, et al
    Comorbidity of common psychiatric disorders and attention-deficit/hyperactivity disorder in Chinese adults.
    Psychiatry Res. 2025;351:116662.
    PubMed     Abstract available
    
    
    August 2025
95. PATEL SES, Haut KM, Lee H, Fisher M, et al
    Social cognition training improves recognition of individual emotions in schizophrenia disorder.
    Psychiatry Res. 2025;352:116711.
    PubMed     Abstract available
    
    
    
96. BLAIN SD, Kent JS, Peyromaure de Bord CA, Sponheim SR, et al
    Social cognitive deficits in schizophrenia, bipolar disorder, and first-degree relatives: A large-sample, multi-task investigation.
    Psychiatry Res. 2025;352:116694.
    PubMed     Abstract available
    
    
    
97. JUST SA, Elvevag B, Pandey S, Nenchev I, et al
    Moving beyond word error rate to evaluate automatic speech recognition in clinical samples: Lessons from research into schizophrenia-spectrum disorders.
    Psychiatry Res. 2025;352:116690.
    PubMed     Abstract available
    
    
    
98. WANG Z, Li J, Wang L, Wei Q, et al
    Comparative Effects of Exercise Modalities on Negative Symptoms in Schizophrenia: A Systematic Review and Network Meta-analysis of 32 RCTs.
    Psychiatry Res. 2025;352:116665.
    PubMed     Abstract available
    
    
    
99. ASENJO-LOBOS C, Arancibia M, Cortes-Jofre M, Huang T, et al
    Comparative efficacy and safety of clozapine vs. risperidone in schizophrenia and related disorders: An updated systematic review.
    Psychiatry Res. 2025;351:116670.
    PubMed     Abstract available
    
    
    July 2025
100. DUDLEY R, White S, Miskin R, Oakes L, et al
     Corrigendum to Hallucinations across sensory domains in people with post-traumatic stress disorder and psychosis, Psychiatry Research, Vol 342, December 2024, 116229.
     Psychiatry Res. 2025;351:116642.
     PubMed    
     
     
     
101. ARSLAN B, Kizilay E, Turan YE, Verim B, et al
     Computational linguistic investigation in schizophrenia and autism spectrum disorders.
     Psychiatry Res. 2025;351:116633.
     PubMed     Abstract available
     
     
     
102. LEATHEM LD, Barch DM, Moran EK, Patel PK, et al
     Cognitive effort-based decision making in schizophrenia and bipolar disorder: Associations with clinical symptoms and cognitive performance.
     Psychiatry Res. 2025;351:116629.
     PubMed     Abstract available
     
     
     
103. CHIU EC, Lee SC
     Effect of community-based reablement program on quality of life for people with schizophrenia: A randomized controlled study.
     Psychiatry Res. 2025;351:116624.
     PubMed     Abstract available
     
     
     June 2025
104. STUDART I, Rasmussen AR
     OCD with psychotic features or schizophrenia with obsessions and compulsions?
     Psychiatry Res. 2025;351:116619.
     PubMed    
     
     
     
105. SUN X, Qiu Y, Ji L, Li M, et al
     Proteomic characterization of plasma exosomes in drug-naive schizophrenia: Insights into psychosis and cognitive dysfunction.
     Psychiatry Res. 2025;351:116611.
     PubMed     Abstract available
     
     
     
106. SU Q, Wang J, Ge H, Li M, et al
     The relationship between inflammation and cognitive function in drug-naive schizophrenia with or without pre-metabolic syndrome.
     Psychiatry Res. 2025;351:116604.
     PubMed     Abstract available
     
     
     
107. KOTWANI A, Wojtalik JA, Gunzler DD, Smith MJ, et al
     Social cognition as a mediator between neurocognition and functional outcome in early course schizophrenia.
     Psychiatry Res. 2025;351:116594.
     PubMed     Abstract available
     
     
     
108. JACOBSEN SL, Kohler-Forsberg O, Danielsen AA, Rohde C, et al
     Efficacy and safety of GLP1-ras compared to SGLT2is and DPP-4is in individuals with schizophrenia and diabetes: A Danish nationwide target-trial emulation study.
     Psychiatry Res. 2025;351:116592.
     PubMed     Abstract available
     
     
     
109. AL-KURAISHY HM, Mohammed HA, Sulaiman GM, Jabir MS, et al
     Targeting of inflammation and prostaglandins by nonsteroidal anti-inflammatory drugs in schizophrenia: A narrative review.
     Psychiatry Res. 2025;351:116575.
     PubMed     Abstract available
     
     
     May 2025
110. PILON F, Boisvert M, Mottron L, Potvin S, et al
     A fMRI meta-analysis of emotion processing in the psychosis spectrum reveals no significant alterations in at-risk individuals.
     Psychiatry Res. 2025;351:116565.
     PubMed     Abstract available
     
     
     
111. DODGSON G, Singh A, Barclay N, Birkett L, et al
     Managing unusual sensory experiences in at-risk mental state for psychosis in England: A parallel group, single-blind, randomised controlled feasibility trial.
     Psychiatry Res. 2025;351:116564.
     PubMed     Abstract available
     
     
     
112. SAITOH K, Lajnef M, Boukouaci W, Andre M, et al
     Pro-inflammatory processes and metabolic syndrome: combined risk of resistance to treatment in patients with schizophrenia from the FACE-SZ cohort.
     Psychiatry Res. 2025;350:116557.
     PubMed     Abstract available
     
     
     
113. CHEN B, Tan XW, Tor PC
     Effects of dose on early treatment response to bifrontal electroconvulsive therapy in Schizophrenia: A retrospective study.
     Psychiatry Res. 2025;350:116554.
     PubMed     Abstract available
     
     
     
114. CORONADO-MONTOYA S, Abdel-Baki A, Bodson-Clermont P, Boucher-Roy D, et al
     A pilot randomized controlled trial of a digital cannabis harm reduction intervention for young adults with first-episode psychosis who use cannabis.
     Psychiatry Res. 2025;350:116553.
     PubMed     Abstract available
     
     
     
115. TOTZEK JF, Shah JL, Young AL, Malla A, et al
     From resting-state functional hippocampal centrality to functional outcome: An extended neurocognitive model of psychosis.
     Psychiatry Res. 2025;350:116538.
     PubMed     Abstract available
     
     
     
116. GUTIERREZ G, Garcia de Jalon E, Aranguren L, Corrales A, et al
     Corrigendum to 'Antipsychotic discontinuation in nonaffective first-episode psychosis after clinical remission: Insights from the PEPsNa naturalistic study' [ Psychiatry Research volume 342 (December 2024) 1-10/116261].
     Psychiatry Res. 2025 May 16:116539. doi: 10.1016/j.psychres.2025.116539.
     PubMed    
     
     
     
117. LUO H, Li YL, Luo XJ, Xia L, et al
     The efficacy of psychoeducation-based programs on internalized stigma in patients with schizophrenia: A systematic review and meta-analysis.
     Psychiatry Res. 2025;350:116540.
     PubMed     Abstract available
     
     
     
118. HOFMANN AB, Dorner M, Klassen PE, Machetanz L, et al
     RIPTOSO: The development of a screening tool for adverse events during forensic-psychiatric inpatient treatments of offenders with schizophrenia spectrum disorders.
     Psychiatry Res. 2025;350:116537.
     PubMed     Abstract available
     
     
     
119. BERE M, Rossell SL, Toh WL
     Corrigendum to Cognition in relation to non-auditory or multisensory hallucinations in schizophrenia-spectrum disorders: A scoping review.
     Psychiatry Res. 2025;349:116526.
     PubMed    
     
     
     
120. PERALTA V, de Jalon EG, Moreno-Izco L, Peralta D, et al
     Corrigendum to 'A clinical staging model of psychotic disorders based on a long-term follow-up of first-admission psychosis: A validation study' Psychiatry Res. 2023; 322:115109.
     Psychiatry Res. 2025;349:116530.
     PubMed    
     
     
     April 2025
121. DEMIRLI E, Ahmed AO, Serper M
     Personal recovery and future self-continuity in individuals with schizophrenia.
     Psychiatry Res. 2025;348:116510.
     PubMed     Abstract available
     
     
     
122. PELIZZA L, Leuci E, Quattrone E, Palmisano D, et al
     Compulsory admission as access to early intervention service for patients with first episode psychosis: What relevance for clinical outcomes? Further findings from the Pr-EP program.
     Psychiatry Res. 2025;349:116507.
     PubMed     Abstract available
     
     
     
123. SALGADO-PINEDA P, Barbosa L, Hostalet N, Garcia-Leon MA, et al
     An ontogenetic role for Broca's and related speech areas in schizophrenic auditory hallucinations? Evidence from sulcal pits analysis.
     Psychiatry Res. 2025;348:116502.
     PubMed     Abstract available
     
     
     
124. CAO C, Liu W, Hou C, Chen Y, et al
     Disrupted default mode network connectivity and its role in negative symptoms of schizophrenia.
     Psychiatry Res. 2025;348:116489.
     PubMed     Abstract available
     
     
     
125. LU J, Gou N, Zhang S, Zhou J, et al
     Dysfunctional striatal-temporal connectivity is associated with a higher risk for violence in patients with schizophrenia.
     Psychiatry Res. 2025;348:116488.
     PubMed     Abstract available
     
     
     March 2025
126. SIMGE UO, Burcu V, Aybuke K, Ezgi C, et al
     Clinical high risk for psychosis in bipolar disorder: Clinical features, cognition and functioning.
     Psychiatry Res. 2025;348:116478.
     PubMed     Abstract available
     
     
     
127. SHAKER NM, Aly El-Gabry D, Abdel Aziz K, Hashem R, et al
     Clinical and neuroradiological differences in obsessive compulsive disorder with and without psychosis.
     Psychiatry Res. 2025;348:116472.
     PubMed     Abstract available
     
     
     
128. KANE JM, Rubio JM, Casciano J, Dotiwala Z, et al
     Real-world outcomes and practice patterns among patients with schizophrenia when switched from oral antipsychotics to long-acting injectable formulations after hospitalization.
     Psychiatry Res. 2025;348:116455.
     PubMed     Abstract available
     
     
     
129. APRILE SF, Rodolico A, Di Francesco A, Varrasi S, et al
     Oral versus long-acting injectable antipsychotics in schizophrenia spectrum disorders: A systematic review of patients' subjective experiences.
     Psychiatry Res. 2025;348:116460.
     PubMed     Abstract available
     
     
     
130. LINDSTROM S, Nordgaard J, Berge J
     Transition from schizotypal disorder to non-affective psychotic disorders including schizophrenia: A nationwide Swedish cohort study.
     Psychiatry Res. 2025;348:116470.
     PubMed     Abstract available
     
     
     
131. BAILEY A, Bauer BW, Mittal VA, Ellman LM, et al
     Interpersonal difficulties and suicidal ideation in young people at clinical high-risk for psychosis and help-seeking clinical controls.
     Psychiatry Res. 2025;348:116467.
     PubMed     Abstract available
     
     
     
132. NEERGAARD KD, Zemla JC, Victor Ortiz-Garcia de la F, Lubrini G, et al
     Novel computational measure of semantic fluency performance associated with first-episode of psychosis.
     Psychiatry Res. 2025;348:116462.
     PubMed     Abstract available
     
     
     
133. SUDAR FP, Zekerallah SS, Paulzen M, Mathiak K, et al
     Unraveling antipsychotic induced weight gain in schizophrenia - A proof-of-concept study exploring the impact of the cumulative historical occupancy of different receptors by antipsychotics.
     Psychiatry Res. 2025;348:116452.
     PubMed     Abstract available
     
     
     
134. SHIMADA T, Ito S, Yamanushi A, Koizumi A, et al
     Effect of aerobic exercise versus cognitive remediation versus a combination of both on cognition among patients with schizophrenia: A three-arm, randomized controlled study.
     Psychiatry Res. 2025;348:116454.
     PubMed     Abstract available
     
     
     
135. GOLDSTEIN KE, Pietrzak RH, Aladin S, Ng S, et al
     Neuro- and social-cognition in schizotypal personality disorder and schizophrenia: A spectrum of severity.
     Psychiatry Res. 2025;348:116445.
     PubMed     Abstract available
     
     
     
136. MEWENGKANG A, Pandolos T, Sengkey MM, Sengkey SB, et al
     Sleep quality vs. mental health: A complex relationship with psychosis.
     Psychiatry Res. 2025;348:116441.
     PubMed    
     
     
     
137. SENTHIL KUMAR L, Chen B, Tan X, Tor PC, et al
     Response to electroconvulsive therapy is not consistently replicated across multiple treatment courses.
     Psychiatry Res. 2025;345:116374.
     PubMed     Abstract available
     
     
     
138. LOHMAN MC, Scott V, Verma M, Jones P, et al
     Distribution and correlates of long-acting injectable antipsychotic use among community mental health center patients.
     Psychiatry Res. 2025;345:116378.
     PubMed     Abstract available
     
     
     February 2025
139. SOLBERG A, Ottesen A, Barrett EA, Kristiansen I, et al
     Trajectories of suicidal behavior and their clinical correlates in the early phases of schizophrenia spectrum disorders.
     Psychiatry Res. 2025;347:116409.
     PubMed     Abstract available
     
     
     
140. DAMIANI S, D'Imperio A, Radua J, Fortea L, et al
     A systematic review and synthesis of 489 studies investigating treatments for negative symptoms in the schizophrenia spectrum: Trial designs, demographics and clinical characteristics.
     Psychiatry Res. 2025;347:116406.
     PubMed     Abstract available
     
     
     
141. CAI C, Zhao P, Patel C, Benson C, et al
     Latent variable analysis of adherence to antipsychotics among south carolina medicaid beneficiaries with schizophrenia or schizoaffective disorder.
     Psychiatry Res. 2025;346:116402.
     PubMed     Abstract available
     
     
     
142. HANDEST R, Molstrom IM, Henriksen MG, Nordgaard J, et al
     Revisiting the relationship between impaired social functioning and psychopathology in schizophrenia.
     Psychiatry Res. 2025;346:116389.
     PubMed     Abstract available
     
     
     January 2025
143. HUIZER K, Soni S, Schmidt MA, Cakici N, et al
     Potential benefits of ketone therapy as a novel immunometabolic treatment for schizophrenia.
     Psychiatry Res. 2025;345:116379.
     PubMed     Abstract available
     
     
     
144. HWANG H, Kim SM, Kim HJ, Han DH, et al
     Comparison of attention and brain functional connectivity between patient groups with schizophrenia and attention deficit hyperactivity disorder.
     Psychiatry Res. 2025;345:116376.
     PubMed     Abstract available
     
     
     
145. BERISHA F, Paquin V, Gold I, Misic B, et al
     Exploring delusional themes and other symptoms in first episode psychosis: A network analysis over two timepoints.
     Psychiatry Res. 2025;344:116349.
     PubMed     Abstract available
     
     
     
146. GRENDAS LN, Olaviaga A, Chiapella LC, Daray FM, et al
     Incidence rate of suicidal behavior stratified by diagnosis among high-risk patients.
     Psychiatry Res. 2025;343:116310.
     PubMed     Abstract available
     
     
     December 2024
147. LI J, He J, Ren H, Li Z, et al
     Multilayer network instability underlying persistent auditory verbal hallucinations in schizophrenia.
     Psychiatry Res. 2024;344:116351.
     PubMed     Abstract available
     
     
     
148. ZHANG H, He R, Palominos C, Hsu N, et al
     The structure of meaning in schizophrenia: A study of spontaneous speech in Chinese.
     Psychiatry Res. 2024;344:116347.
     PubMed     Abstract available
     
     
     
149. HSIAO CY, Wu KY, Chiu CK, Lu HL, et al
     Development and validation of a schizophrenia literacy scale for individuals diagnosed with schizophrenia.
     Psychiatry Res. 2024;344:116344.
     PubMed     Abstract available
     
     
     
150. PIETERS LE, Deenik J, Hoogendoorn AW, van Someren EJW, et al
     Sleep and physical activity patterns in relation to daily-life symptoms in psychosis: An actigraphy and experience sampling study.
     Psychiatry Res. 2024;344:116320.
     PubMed     Abstract available
     
     
     
151. GARCIA-FERNANDEZ L, Romero-Ferreiro V, Padilla S, Wynn R, et al
     Transcranial direct current stimulation (tDCS) enhances cognitive function in schizophrenia: A randomized double-blind sham-controlled trial.
     Psychiatry Res. 2024;344:116308.
     PubMed     Abstract available
     
     
     
152. WYSOKINSKI A, Dreczka J
     Clozapine Toxicity Predictor: Deep neural network model predicting clozapine toxicity and its therapeutic dose range.
     Psychiatry Res. 2024;342:116256.
     PubMed     Abstract available
     
     
     
153. SOLDEVILA-MATIAS P, Sanchez-Orti JV, Correa-Ghisays P, Balanza-Martinez V, et al
     Exercise as a promoter of neurocognitive improvement in people with psychiatric disorders and comorbid obesity: A randomized controlled trial.
     Psychiatry Res. 2024;342:116226.
     PubMed     Abstract available
     
     
     
154. FLORENTIN S, Neumark Y, Roe D, Rosca P, et al
     The relationship between community-based psychiatric rehabilitation pathways and re-hospitalization trajectories: A three-decade follow-up.
     Psychiatry Res. 2024;342:116216.
     PubMed     Abstract available
     
     
     
155. PISANU C, Congiu D, Meloni A, Paribello P, et al
     Sex differences in shared genetic determinants between severe mental disorders and metabolic traits.
     Psychiatry Res. 2024;342:116195.
     PubMed     Abstract available
     
     
     November 2024
156. SOURANDER A, Silwal S, Surcel HM, Hinkka-Yli-Salomaki S, et al
     Maternal vitamin B12 during pregnancy and schizophrenia in offspring.
     Psychiatry Res. 2024;344:116284.
     PubMed     Abstract available
     
     
     
157. MORITZ S, Leucht S, Hoyer L, Schmotz S, et al
     Towards the DSM-6: The intersection of OCD and psychosis. Expert perspectives on insight in the diagnosis of OCD.
     Psychiatry Res. 2024;344:116306.
     PubMed     Abstract available
     
     
     
158. KHOODORUTH MAS, Hussain T, Ouanes S, Chut-Kai Khoodoruth NW, et al
     Peripheral inflammatory and metabolic markers as potential biomarkers in treatment-resistant schizophrenia: Insights from a Qatari Cohort.
     Psychiatry Res. 2024;344:116307.
     PubMed     Abstract available
     
     
     
159. KUMAR M, Choudhary H, Chawla N
     Association of antipsychotic formulations with sudden cardiac death in patients with schizophrenia: A nationwide population-based case-control study: Letter to the editor.
     Psychiatry Res. 2024;343:116299.
     PubMed    
     
     
     
160. GONCALVES CC, Waters Z, Quirk SE, Haddad PM, et al
     Barriers and facilitators to mental health care access and engagement for LGBTQA+ people with psychosis: A scoping review.
     Psychiatry Res. 2024;343:116281.
     PubMed     Abstract available
     
     
     
161. REANGSING C, Wongsuraprakit S, Punsuwun S, Oerther S, et al
     Effects of mindfulness-based interventions (MBIs) on psychotic symptoms and psychological outcomes in patients with schizophrenia spectrum disorders: A systematic review and meta-analysis.
     Psychiatry Res. 2024;342:116272.
     PubMed     Abstract available
     
     
     
162. LAMARCA M, Espinosa V, Acuna V, Vila-Badia R, et al
     Reducing self-stigma in psychosis: A systematic review and meta-analysis of psychological interventions.
     Psychiatry Res. 2024;342:116262.
     PubMed     Abstract available
     
     
     
163. BERE M, Rossell SL, Toh WL
     Cognition in relation to non-auditory or multisensory hallucinations in schizophrenia-spectrum disorders: A scoping review.
     Psychiatry Res. 2024;342:116268.
     PubMed     Abstract available
     
     
     
164. ABRAHAM T, Gill H, Wood L
     Psychosocial interventions offered across inpatient and crisis settings to the social networks of service users with psychosis: A systematic review.
     Psychiatry Res. 2024;343:116267.
     PubMed     Abstract available
     
     
     
165. GUTIERREZ G, Garcia de Jalon E, Aranguren L, Corrales A, et al
     Antipsychotic discontinuation in nonaffective first-episode psychosis after clinical remission: Insights from the PEPsNa naturalistic study.
     Psychiatry Res. 2024;342:116261.
     PubMed     Abstract available
     
     
     
166. PUGH SL, Chandler C, Cohen AS, Diaz-Asper C, et al
     Assessing dimensions of thought disorder with large language models: The tradeoff of accuracy and consistency.
     Psychiatry Res. 2024;341:116119.
     PubMed     Abstract available
     
     
     October 2024
167. CALZAVARA PINTON I, Nibbio G, Bertoni L, Cicale A, et al
     The economic burden of schizophrenia spectrum disorders: clinical and functional correlates and predictors of direct costs. A retrospective longitudinal study.
     Psychiatry Res. 2024;342:116240.
     PubMed     Abstract available
     
     
     
168. DEMIRLEK C, Verim B, Zorlu N, Demir M, et al
     Functional brain networks in clinical high-risk for bipolar disorder and psychosis.
     Psychiatry Res. 2024;342:116251.
     PubMed     Abstract available
     
     
     
169. KISIANG'ANI IB, Aden M, Mwangi HR, Akena D, et al
     Exploring psychotic symptoms among substance-naive individuals and recent abstainers without a psychosis diagnosis: A cross-country study across Kenya, Uganda, Ethiopia, and South Africa.
     Psychiatry Res. 2024;342:116253.
     PubMed     Abstract available
     
     
     
170. THIBAUDEAU E, Bowie CR, Montreuil T, Baer L, et al
     Acceptability, engagement, and efficacy of cognitive remediation for cognitive outcomes in young adults with first-episode psychosis and social anxiety: A randomized-controlled trial.
     Psychiatry Res. 2024;342:116243.
     PubMed     Abstract available
     
     
     
171. GONZALES L, Saperstein AM, Qian M, Gorecki A, et al
     Psychiatric and functional correlates of stigma associated with cognitive impairment in schizophrenia.
     Psychiatry Res. 2024;342:116233.
     PubMed     Abstract available
     
     
     
172. CIOFFI L, Wein PY, Miller SA, Fagan S, et al
     Clinical, neurocognitive, neurobiological and functional correlates of sleep difficulties in individuals at-risk for psychosis and mania: A scoping review.
     Psychiatry Res. 2024;342:116235.
     PubMed     Abstract available
     
     
     
173. DUDLEY R, White S, Miskin R, Oakes L, et al
     Hallucinations across sensory domains in people with post-traumatic stress disorder and psychosis.
     Psychiatry Res. 2024;342:116229.
     PubMed     Abstract available
     
     
     
174. TORREY EF, Simmons W, Dailey L
     Schizophrenia, clinical and basic research at NIMH: A 75 Year retrospective.
     Psychiatry Res. 2024;342:116225.
     PubMed     Abstract available
     
     
     
175. SARNYAI Z, Ben-Shachar D
     Schizophrenia, a disease of impaired dynamic metabolic flexibility: A new mechanistic framework.
     Psychiatry Res. 2024;342:116220.
     PubMed     Abstract available
     
     
     
176. BERA S, Yang AB, Chung D, Arnesen R, et al
     Duffy-null associated neutrophil count and antipsychotic use.
     Psychiatry Res. 2024;340:116146.
     PubMed    
     
     
     September 2024
177. ARMARIO A, Nadal R, Fuentes S, Visa J, et al
     Prenatal immune activation in rats and adult exposure to inescapable shocks reveal sex-dependent effects on fear conditioning that might be relevant for schizophrenia.
     Psychiatry Res. 2024;342:116219.
     PubMed     Abstract available
     
     
     
178. GIAMPETRUZZI E, Walker EF, Addington J, Bearden CE, et al
     Impact of adverse childhood experiences on risk for internalizing psychiatric disorders in youth at clinical high-risk for psychosis.
     Psychiatry Res. 2024;342:116214.
     PubMed     Abstract available
     
     
     
179. TEYMOURI K, Ebrahimi M, Chen CC, Sriretnakumar V, et al
     Sex-dependent association study of complement C4 gene with treatment-resistant schizophrenia and hospitalization frequency.
     Psychiatry Res. 2024;342:116202.
     PubMed     Abstract available
     
     
     
180. SUKNO FM, Kelly BD, Lane A, Katina S, et al
     Loss of normal facial asymmetry in schizophrenia and bipolar disorder: Implications for development of brain asymmetry in psychotic illness.
     Psychiatry Res. 2024;342:116213.
     PubMed     Abstract available
     
     
     
181. CIUFALO J, Zaccone S, Fatiga G, Caputo GB, et al
     Creative puppet therapy reduces hallucinations in patients diagnosed with schizophrenia: Preliminary findings.
     Psychiatry Res. 2024;342:116211.
     PubMed     Abstract available
     
     
     
182. GLINERT A, Zlidennyy V, Turjeman S, Sharon E, et al
     What's GABA got to do with it? A potential link between the microbiome, schizophrenia, and the endo-cannabinoid system.
     Psychiatry Res. 2024;342:116196.
     PubMed     Abstract available
     
     
     
183. DOMINGUEZ T, Puebla DP, Fresan A, Sheinbaum T, et al
     Why do some Mexicans with psychosis risk symptoms seek mental health care and others do not?
     Psychiatry Res. 2024;342:116199.
     PubMed     Abstract available
     
     
     
184. CASANOVAS F, Dinamarca F, Posso M, Mane A, et al
     Cancer characteristics in patients with schizophrenia: a 25-year retrospective analysis.
     Psychiatry Res. 2024;342:116206.
     PubMed     Abstract available
     
     
     
185. MEHTA UM, Roy N, Bahuguna A, Kotambail A, et al
     Incremental predictive value of genetic risk and functional brain connectivity in determining antipsychotic response in schizophrenia.
     Psychiatry Res. 2024;342:116201.
     PubMed     Abstract available
     
     
     
186. TANG JMY, Chiu KKY, Yang C, Cheung DSK, et al
     Social cognition interventions for patients with first-episode psychosis: A scoping review.
     Psychiatry Res. 2024;342:116191.
     PubMed     Abstract available
     
     
     
187. KRISTENSEN TD, Mager FM, Ambrosen KS, Barber AD, et al
     Cognitive profiles across the psychosis continuum.
     Psychiatry Res. 2024;342:116168.
     PubMed     Abstract available
     
     
     
188. D'ANDREA G, Ouellet-Plamondon C, Villeneuve M, Shah JL, et al
     Joint-trajectories of clinical severity, social functioning and cannabis use in first-episode psychosis: A 5-year longitudinal study in 2 urban early intervention services.
     Psychiatry Res. 2024;342:116184.
     PubMed     Abstract available
     
     
     
189. VALT C, Lopez-Caballero F, Tavella A, Altamura M, et al
     Abnormal inter-hemispheric effective connectivity from left to right auditory regions during Mismatch Negativity (MMN) tasks in psychosis.
     Psychiatry Res. 2024;342:116189.
     PubMed     Abstract available
     
     
     
190. BORNHEIMER LA, Bagge CL, Overholser J, Brdar NM, et al
     Demographic and clinical characteristics of individuals with psychosis symptoms who died by suicide: Findings of a psychological autopsy study.
     Psychiatry Res. 2024;342:116185.
     PubMed     Abstract available
     
     
     
191. HSIEH KP, Liao WL, Ho PS, Lin JW, et al
     Association of antipsychotic formulations with sudden cardiac death in patients with schizophrenia: A nationwide population-based case-control study.
     Psychiatry Res. 2024;342:116171.
     PubMed     Abstract available
     
     
     
192. DE HAAS HJ, Cohen D, de Koning MB, van Weringh G, et al
     Clozapine levels and outcomes in Serbian patients with treatment-resistant psychotic disorders previously treated without measuring clozapine levels (CLOSER).
     Psychiatry Res. 2024;339:116070.
     PubMed     Abstract available
     
     
     
193. PICCHIONI M, Ruiz R, de Girolamo G, Iozzino L, et al
     The predictive validity and temporal characteristics of the HCR-20v3 for inpatient violence in forensic inpatient settings. An international study.
     Psychiatry Res. 2024;339:116079.
     PubMed     Abstract available
     
     
     
194. ZACHOS KA, Choi J, Godin O, Chernega T, et al
     Mitochondrial Biomarkers and Metabolic Syndrome in Bipolar Disorder.
     Psychiatry Res. 2024;339:116063.
     PubMed     Abstract available
     
     
     
195. LUYKX JJ, Tanskanen A, Lahteenvuo M, Manu P, et al
     Dopamine D2 receptor antagonism of antipsychotics and the risk of death due to choking.
     Psychiatry Res. 2024;339:116012.
     PubMed     Abstract available
     
     
     August 2024
196. MORKVED N, Johnsen E, Kroken RA, Joa I, et al
     Childhood trauma types in relation to antipsychotic effectiveness in schizophrenia spectrum disorders: A prospective, pragmatic, randomized controlled study.
     Psychiatry Res. 2024;341:116169.
     PubMed     Abstract available
     
     
     
197. SNELLEKSZ M, Dean B
     Higher levels of AKT-interacting protein in the frontal pole from people with schizophrenia are limited to a sub-group who have a marked deficit in cortical muscarinic M1 receptors.
     Psychiatry Res. 2024;341:116156.
     PubMed     Abstract available
     
     
     
198. MORO L, Sicotte R, Joober R, Malla A, et al
     Trajectories of suicidality during a 2-year early-intervention program for first-episode psychosis: A longitudinal study.
     Psychiatry Res. 2024;340:116148.
     PubMed     Abstract available
     
     
     
199. COHEN S, Goldsmith DR, Ning CS, Addington J, et al
     Sleep disturbance, suicidal ideation and psychosis-risk symptoms in individuals at clinical high risk for psychosis.
     Psychiatry Res. 2024;341:116147.
     PubMed     Abstract available
     
     
     
200. TSUI HKH, Luk SL, Hsiao J, Chan SKW, et al
     Facial emotion perception in individuals with clinical high risk for psychosis compared with healthy controls, first-episode psychosis, and in predicting psychosis transition: A systematic review and meta-analysis.
     Psychiatry Res. 2024;340:116143.
     PubMed     Abstract available
     
     
     
201. GUZMAN A, Klein H, Keefe RS, Horan WP, et al
     Location-based differences in cognition and functional capacity: Consistent levels of impairment in participants with schizophrenia compared to healthy controls.
     Psychiatry Res. 2024;340:116121.
     PubMed     Abstract available
     
     
     
202. GIANNOUCHOS TV, Ohsfeldt RL, Kum HC
     Trends and disparities in emergency department visits for schizophrenia spectrum disorders in Texas from 2019 to 2022.
     Psychiatry Res. 2024;340:116139.
     PubMed    
     
     
     
203. MENDEZ-VICTORIANO G, Zhu Y, Middleton F, Massa PT, et al
     Increased Parenchymal Macrophages are associated with decreased Tyrosine Hydroxylase mRNA levels in the Substantia Nigra of people with Schizophrenia and Bipolar Disorder.
     Psychiatry Res. 2024;340:116141.
     PubMed     Abstract available
     
     
     
204. VITA G, Pollini D, Canozzi A, Papola D, et al
     Efficacy and acceptability of long-acting antipsychotics in acutely ill individuals with schizophrenia-spectrum disorders: A systematic review and network meta-analysis.
     Psychiatry Res. 2024;340:116124.
     PubMed     Abstract available
     
     
     
205. VITA A, Nibbio G, Barlati S
     Conceptualization and characterization of "primary" and "secondary" cognitive impairment in schizophrenia.
     Psychiatry Res. 2024;340:116126.
     PubMed     Abstract available
     
     
     July 2024
206. MAZZAROTTO F, Monteleone P, Minelli A, Mattevi S, et al
     Genetic determinants of coping, resilience and self-esteem in schizophrenia suggest a primary role for social factors and hippocampal neurogenesis.
     Psychiatry Res. 2024;340:116107.
     PubMed     Abstract available
     
     
     
207. GREVE AN, Hemager N, Mortensen EL, Gantriis DL, et al
     Comparing cognition in parents with schizophrenia or bipolar disorder and their 7-year-old offspring.
     Psychiatry Res. 2024;340:116112.
     PubMed     Abstract available
     
     
     
208. LUCARINI V, Grice M, Wehrle S, Cangemi F, et al
     Language in interaction: turn-taking patterns in conversations involving individuals with schizophrenia.
     Psychiatry Res. 2024;339:116102.
     PubMed     Abstract available
     
     
     
209. BLOSE BA, Silverstein SM, Stuart KV, Keane PA, et al
     Association between polygenic risk for schizophrenia and retinal morphology: A cross-sectional analysis of the United Kingdom Biobank.
     Psychiatry Res. 2024;339:116106.
     PubMed     Abstract available
     
     
     
210. FEKIH-ROMDHANE F, Ghrissi F, Abassi B, Loch AA, et al
     Impulsivity as a predictor of clinical and psychological outcomes in a naturalistic prospective cohort of subjects at ultra-high risk (UHR) for psychosis from Tunisia.
     Psychiatry Res. 2024;340:116090.
     PubMed     Abstract available
     
     
     
211. COFFMAN BA, Curtis M, Seebold D, Kocsis J, et al
     Long-latency auditory evoked response amplitudes at first episode of psychosis predict six-month recovery in positive symptom severity.
     Psychiatry Res. 2024;339:116094.
     PubMed     Abstract available
     
     
     
212. LOURENCO PJDS, Bastos TCL, Pizarro AIN, Corredeira RMN, et al
     Feasibility and effectiveness of a 24-weeks outdoor exercise program on the physical and mental health of persons with schizophrenia.
     Psychiatry Res. 2024;339:116093.
     PubMed     Abstract available
     
     
     
213. THELWELL ELR, Dunkerley L, Goodwin R, Giacco D, et al
     Effectiveness of online social networking interventions on social isolation and quality of life of people with psychosis: A systematic review.
     Psychiatry Res. 2024;339:116088.
     PubMed     Abstract available
     
     
     
214. BIAN Y, Kawabata R, Enwright JF, Tsubomoto M, et al
     Expression of activity-regulated transcripts in pyramidal neurons across the cortical visuospatial working memory network in unaffected comparison individuals and individuals with schizophrenia.
     Psychiatry Res. 2024;339:116084.
     PubMed     Abstract available
     
     
     
215. SCHUTZ A, Salahuddin NH, Priller J, Bighelli I, et al
     The role of control groups in non-pharmacological randomised controlled trials of treatment-resistant schizophrenia: A systematic review and meta-analysis.
     Psychiatry Res. 2024;339:116069.
     PubMed     Abstract available
     
     
     
216. SIDDI S, Ochoa S, Laroi F, Lincoln TM, et al
     A cross-national investigation of psychosis-like experiences in five European countries included in the E-CLECTIC study: Psychometric challenges in studying their measurement.
     Psychiatry Res. 2024;339:116072.
     PubMed     Abstract available
     
     
     
217. WANNAN CMJ, Eratne D, Santillo AF, Malpas C, et al
     Plasma neurofilament light protein is differentially associated with age in individuals with treatment-resistant schizophrenia and bipolar affective disorder compared to controls.
     Psychiatry Res. 2024;339:116073.
     PubMed     Abstract available
     
     
     
218. WILTSCHKO M
     Is grammar affected in Schizophrenia?
     Psychiatry Res. 2024;339:116061.
     PubMed    
     
     
     
219. CHAN SKW, Pang TSW, Tsui HKH, Suen YN, et al
     Modeling the effects of treatment resistance and anticholinergic burden on cognitive function domains in patients with schizophrenia.
     Psychiatry Res. 2024;337:115985.
     PubMed     Abstract available
     
     
     June 2024
220. MELISSA B, Sabrina G, Charles-Edouard G, Hind Z, et al
     Clinical characteristics associated with functioning trajectories following admission to a psychiatric institution: A prospective cohort study of individuals with psychosis.
     Psychiatry Res. 2024;339:116062.
     PubMed     Abstract available
     
     
     
221. COLIJN MA
     Genetic testing in individuals experiencing psychosis: A practical guide for psychiatrists.
     Psychiatry Res. 2024;339:116052.
     PubMed    
     
     
     
222. ANDERSEN HG, DellaValle B, Bogehave H, Mogensen PB, et al
     Glycocalyx shedding patterns identifies antipsychotic-naive patients with first-episode psychosis.
     Psychiatry Res. 2024;339:116037.
     PubMed     Abstract available
     
     
     
223. NADER G, Qureshi M, Chaudhary Z, Fischer CE, et al
     Effect of personality traits, psychological resilience and life adversities on lifetime violence trajectories: A novel classification model in schizophrenia.
     Psychiatry Res. 2024;339:116044.
     PubMed     Abstract available
     
     
     
224. CHIEN WT, Chong YY, Bressington D, McMaster CW, et al
     A randomized controlled trial of an acceptance-based, insight-inducing medication adherence therapy (AIM-AT) for adults with early-stage psychosis.
     Psychiatry Res. 2024;339:116046.
     PubMed     Abstract available
     
     
     
225. FERRARA M, Domenicano I, Marchi A, Zaffarami G, et al
     First episode psychoses in people over-35 years old: uncovering potential actionable targets for early intervention services.
     Psychiatry Res. 2024;339:116034.
     PubMed     Abstract available
     
     
     
226. POUSA E, Brebion G, Lopez-Carrilero R, Ruiz AI, et al
     Predictors of clinical insight in first-episode psychosis: Different patterns in men and women.
     Psychiatry Res. 2024;339:116036.
     PubMed     Abstract available
     
     
     
227. HOSTALET N, Gonzalez A, Salgado-Pineda P, Gonzalez-Colom R, et al
     Face-brain correlates as potential sex-specific biomarkers for schizophrenia and bipolar disorder.
     Psychiatry Res. 2024;339:116027.
     PubMed     Abstract available
     
     
     
228. BUCCI S, Berry N, Ainsworth J, Berry K, et al
     Effects of Actissist, a digital health intervention for early psychosis: A randomized clinical trial.
     Psychiatry Res. 2024;339:116025.
     PubMed     Abstract available
     
     
     
229. CHENG KY, Robinson N, Ploner A, Kuja-Halkola R, et al
     Impact of traumatic brain injury on risk for schizophrenia and bipolar disorder.
     Psychiatry Res. 2024;339:115990.
     PubMed     Abstract available
     
     
     
230. ROTELLA F, Falone A, Cassioli E, Mannucci E, et al
     The effect of differences in trial design on estimates of efficacy of olanzapine in randomized studies.
     Psychiatry Res. 2024;336:115895.
     PubMed     Abstract available
     
     
     
231. MISHRA A, Maiti R, Ramasubbu MK, Srinivasan A, et al
     Evaluation of the pharmacodynamic interaction effect of augmentation agents with clozapine in patients with treatment-resistant schizophrenia: A simulation study of clinical data.
     Psychiatry Res. 2024;338:115989.
     PubMed     Abstract available
     
     
     May 2024
232. WASTLER HM, Mengda Y, Pan X, Bornheimer LA, et al
     Trajectories of suicidal risk among individuals with first-episode psychosis: Relationship to recovery and symptoms.
     Psychiatry Res. 2024;338:115978.
     PubMed     Abstract available
     
     
     
233. COLLINS M, Bartholomeusz C, Mei C, Kerr M, et al
     Erythrocyte membrane fatty acid concentrations and myelin integrity in young people at ultra-high risk of psychosis.
     Psychiatry Res. 2024;337:115966.
     PubMed     Abstract available
     
     
     
234. SANGIMINO M, Babbitt K, Lee HS, Park S, et al
     Bodily experiences of trauma and psychosis risk.
     Psychiatry Res. 2024;337:115961.
     PubMed     Abstract available
     
     
     
235. OH H, Karcher NR, Li Verdugo J, Botello R, et al
     Ethno-racial disparities in psychosis-like experiences among students in higher education: Findings from the Healthy Minds Study 2020-2021.
     Psychiatry Res. 2024;337:115959.
     PubMed     Abstract available
     
     
     
236. WU Y, Zhang CY, Zhang Y, Chen R, et al
     Genomic landscape and functional characterization of structural variations in schizophrenia and bipolar disorder.
     Psychiatry Res. 2024;337:115929.
     PubMed     Abstract available
     
     
     
237. BULDUK BK, Tortajada J, Valiente-Palleja A, Callado LF, et al
     High number of mitochondrial DNA alterations in postmortem brain tissue of patients with schizophrenia compared to healthy controls.
     Psychiatry Res. 2024;337:115928.
     PubMed     Abstract available
     
     
     April 2024
238. GUO H, Zhong S, Lam ST, Wang N, et al
     Trends in violent offending among people with schizophrenia: A 10-year ecological study.
     Psychiatry Res. 2024;337:115935.
     PubMed     Abstract available
     
     
     
239. BRADLEY ER, Portanova J, Woolley JD, Buck B, et al
     Quantifying abnormal emotion processing: A novel computational assessment method and application in schizophrenia.
     Psychiatry Res. 2024;336:115893.
     PubMed     Abstract available
     
     
     
240. SMITH LC, Mateos AC, Due AS, Bergstrom J, et al
     Immersive virtual reality in the treatment of auditory hallucinations: A PRISMA scoping review.
     Psychiatry Res. 2024;334:115834.
     PubMed     Abstract available
     
     
     March 2024
241. SPINAZZOLA E, Quattrone D, Quattrone A, Murray RM, et al
     The increased incidence of psychosis during the COVID-19 pandemic in South London: The role of heavy cannabis use.
     Psychiatry Res. 2024;336:115869.
     PubMed    
     
     
     
242. HAMZEHPOUR L, Bohn T, Dutsch V, Jaspers L, et al
     From brain to body: exploring the connection between altered reward processing and physical fitness in schizophrenia.
     Psychiatry Res. 2024;335:115877.
     PubMed     Abstract available
     
     
     
243. GALLEGO JA, McNamara RK, Blanco EA, Castaneda S, et al
     Evidence for cytokine dysregulation in schizophrenia spectrum disorders: A comparison of cerebrospinal fluid and blood samples.
     Psychiatry Res. 2024;335:115871.
     PubMed     Abstract available
     
     
     
244. SEFIK E, Guest RM, Aberizk K, Espana R, et al
     Psychosis spectrum symptoms among individuals with schizophrenia-associated copy number variants and evidence of cerebellar correlates of symptom severity.
     Psychiatry Res. 2024;335:115867.
     PubMed     Abstract available
     
     
     
245. SETHI S, Wakeham D, Ketter T, Hooshmand F, et al
     Ketogenic Diet Intervention on Metabolic and Psychiatric Health in Bipolar and Schizophrenia: A Pilot Trial.
     Psychiatry Res. 2024;335:115866.
     PubMed     Abstract available
     
     
     
246. YANG H, Zhu D, Liu Y, Xu Z, et al
     Employing graph attention networks to decode psycho-metabolic interactions in Schizophrenia.
     Psychiatry Res. 2024;335:115841.
     PubMed     Abstract available
     
     
     
247. KISHI T, Citrome L, Sakuma K, Iwata N, et al
     A comparison of recurrence rates after discontinuation of second-generation antipsychotic long-acting injectable versus corresponding oral antipsychotic in the maintenance treatment of bipolar disorder: A systematic review.
     Psychiatry Res. 2024;333:115761.
     PubMed     Abstract available
     
     
     February 2024
248. GORORA ME, Dalkner N, Moore RC, Depp CA, et al
     A meta-cognitive Wisconsin Card Sorting Test in people with schizophrenia and bipolar disorder: Self-assessment of sorting performance.
     Psychiatry Res. 2024;334:115831.
     PubMed     Abstract available
     
     
     
249. QIN K, Yu Y, Cai H, Li J, et al
     Effectiveness of mindfulness-based intervention in schizophrenia: A meta-analysis of randomized controlled trials.
     Psychiatry Res. 2024;334:115808.
     PubMed     Abstract available
     
     
     
250. KIKUCHI Y, Komatsu H, Otsuka Y, Ito F, et al
     Effect of concomitant use of valproic acid during clozapine initiation on clozapine-induced inflammation among Japanese patients with schizophrenia.
     Psychiatry Res. 2024;334:115810.
     PubMed     Abstract available
     
     
     
251. GOODING DC, Mohrbacher DA, Umucu E, Van Hulle CA, et al
     Ethnoracialized group differences in attitudes and knowledge about schizophrenia and willingness to engage in biomarker research: The UBIGR Study.
     Psychiatry Res. 2024;334:115776.
     PubMed     Abstract available
     
     
     
252. HYATT AS, Mulvaney-Day N, Chow CM, Cook BL, et al
     Association between electronic nicotine product use and subsequent first episode psychosis.
     Psychiatry Res. 2024;334:115785.
     PubMed     Abstract available
     
     
     
253. KWAK PP, Ibarra C, Hernandez A, Carrasco J, et al
     Differences in metabolic biomarkers in people with schizophrenia who are of Mexican descent compared to non-Hispanic whites.
     Psychiatry Res. 2024;334:115788.
     PubMed     Abstract available
     
     
     
254. QUIRINO AHA, da Rocha MEC, Andrade AGM, E Souza FGM, et al
     The demonstrated association: Cannabis use and onset of psychosis in the study by Medeiros et al., refuting the reverse notion.
     Psychiatry Res. 2024;334:115771.
     PubMed    
     
     
     January 2024
255. HE R, Palominos C, Zhang H, Alonso-Sanchez MF, et al
     Navigating the semantic space: Unraveling the structure of meaning in psychosis using different computational language models.
     Psychiatry Res. 2024;333:115752.
     PubMed     Abstract available
     
     
     
256. KOS C, Bais L, Klaasen N, Opmeer E, et al
     Effects of right prefrontal theta-burst transcranial magnetic stimulation or transcranial direct current stimulation on apathy in patients with schizophrenia: A multicenter RCT.
     Psychiatry Res. 2024;333:115743.
     PubMed     Abstract available
     
     
     
257. YI S, Wang Q, Wang W, Hong C, et al
     Efficacy of repetitive transcranial magnetic stimulation (rTMS) on negative symptoms and cognitive functioning in schizophrenia: An umbrella review of systematic reviews and meta-analyses.
     Psychiatry Res. 2024;333:115728.
     PubMed     Abstract available
     
     
     
258. TOUMAIAN M, Covanis P, Mantas A, Karantinos T, et al
     Multisensory integration deficits in Schizophrenia and Autism evidenced in behaviour but not event related potentials.
     Psychiatry Res. 2024;332:115727.
     PubMed     Abstract available
     
     
     
259. PROHENS L, Rodriguez N, Segura AG, Martinez-Pinteno A, et al
     Gene expression imputation provides clinical and biological insights into treatment-resistant schizophrenia polygenic risk.
     Psychiatry Res. 2024;332:115722.
     PubMed     Abstract available
     
     
     
260. JEROME L, Matanov A, Bird V, Priebe S, et al
     Comparison of subjective quality of life domains in schizophrenia, mood, and anxiety disorders; an individual patient data meta-analysis.
     Psychiatry Res. 2024;332:115707.
     PubMed     Abstract available
     
     
     
261. CHU RST, Chong RCH, Chang DHH, Shan Leung AL, et al
     The risk of stroke and post-stroke mortality in people with schizophrenia: A systematic review and meta-analysis study.
     Psychiatry Res. 2024;332:115713.
     PubMed     Abstract available
     
     
     
262. SETIEN-SUERO E, Ayesa-Arriola R, Pena J, Ojeda N, et al
     Premorbid adjustment as predictor of long-term functionality: Findings from a 10-year follow-up study in the PAFIP-cohort.
     Psychiatry Res. 2024;331:115674.
     PubMed     Abstract available
     
     
     
263. MASTELLARI T, Saint-Dizier C, Fovet T, Geoffroy PA, et al
     Exploring seasonality in catatonia diagnosis: Evidence from a large-scale population study.
     Psychiatry Res. 2024;331:115652.
     PubMed     Abstract available
     
     
     December 2023
264. WANG Y, Zhang X
     The role of immune inflammation in electroconvulsive therapy for schizophrenia: Treatment mechanism, and relationship with clinical efficacy: Immune-inflammation in ECT for schizophrenia.
     Psychiatry Res. 2023;332:115708.
     PubMed     Abstract available
     
     
     
265. VGONTZAS AN, Paschalidou A, Simos PG, Anastasaki M, et al
     Impact of long-acting injectable antipsychotics vs. oral medication on relapses of patients with psychosis and bipolar disorder.
     Psychiatry Res. 2023;332:115676.
     PubMed     Abstract available
     
     
     
266. TORREY EF
     Did the human genome project affect research on Schizophrenia?
     Psychiatry Res. 2023;333:115691.
     PubMed     Abstract available
     
     
     
267. KIM WS, Shen J, Tsogt U, Odkhuu S, et al
     Altered thalamic volumes and functional connectivity in the recovered patients with psychosis.
     Psychiatry Res. 2023;331:115688.
     PubMed     Abstract available
     
     
     
268. ZHOU D, Xie H, Chen L, Zhu Z, et al
     The cognitive improvement in patients with schizophrenia following low-intensity repetitive transcranial magnetic stimulation could last for 6 months: A randomized controlled trial.
     Psychiatry Res. 2023;332:115672.
     PubMed     Abstract available
     
     
     
269. CHEN Y, Zhang L, Sun Y, Wang W, et al
     Prevalence of constipation in patients with schizophrenia: A systematic review and meta-analysis.
     Psychiatry Res. 2023;331:115659.
     PubMed    
     
     
     
270. DE MEDEIROS MW, Andrade JC, Haddad NM, Mendonca M, et al
     Cannabis use influences disorganized symptoms severity but not transition in a cohort of non-help-seeking individuals at-risk for psychosis from Sao Paulo, Brazil.
     Psychiatry Res. 2023;331:115665.
     PubMed     Abstract available
     
     
     
271. DEAN B, Duce J, Li QX, Masters CL, et al
     Lower levels of soluble beta-amyloid precursor protein, but not beta-amyloid, in the frontal cortex in schizophrenia.
     Psychiatry Res. 2023;331:115656.
     PubMed     Abstract available
     
     
     
272. FENG XZ, Li Z, Li ZY, Wang K, et al
     Effectiveness and safety of second-generation antipsychotics for psychiatric disorders apart from schizophrenia: A systematic review and meta-analysis.
     Psychiatry Res. 2023;332:115637.
     PubMed     Abstract available
     
     
     
273. VINOGRADOV S
     Harnessing neuroplasticity.
     Psychiatry Res. 2023;330:115607.
     PubMed     Abstract available
     
     
     
274. STAFFORD E, Jakob S, Gur RE, Corcoran CM, et al
     Securing direct stakeholder feedback to inform clinical research in serious mental illness: Results of a patient and family perspectives survey.
     Psychiatry Res. 2023;330:115574.
     PubMed     Abstract available
     
     
     November 2023
275. GROENING JM, Denton E, Parvaiz R, Brunet DL, et al
     A systematic evidence map of the association between cannabis use and psychosis-related outcomes across the psychosis continuum: An umbrella review of systematic reviews and meta-analyses.
     Psychiatry Res. 2023;331:115626.
     PubMed     Abstract available
     
     
     
276. LAMANNA-RAMA N, Romero-Miguel D, Casquero-Veiga M, MacDowell KS, et al
     THC improves behavioural schizophrenia-like deficits that CBD fails to overcome: a comprehensive multilevel approach using the Poly I:C maternal immune activation.
     Psychiatry Res. 2023;331:115643.
     PubMed     Abstract available
     
     
     
277. WEI Z, Wang Y, Hu L, Wang Y, et al
     Incidence, prevalence, and mortality of schizophrenia from 2016 to 2020 in Shandong, China.
     Psychiatry Res. 2023;331:115612.
     PubMed     Abstract available
     
     
     
278. LEE J, Xue X, Au E, McIntyre WB, et al
     Central insulin dysregulation in antipsychotic-naive first-episode psychosis: In silico exploration of gene expression signatures.
     Psychiatry Res. 2023;331:115636.
     PubMed     Abstract available
     
     
     
279. CUESTA MJ, Gil-Berrozpe GJ, Sanchez-Torres AM, Moreno-Izco L, et al
     20-Year trajectories of six psychopathological dimensions in patients with first-episode psychosis: Could they be predicted?
     Psychiatry Res. 2023;331:115614.
     PubMed     Abstract available
     
     
     
280. HU Q, Jiao X, Zhou J, Tang Y, et al
     Low-frequency repetitive transcranial magnetic stimulation over the right orbitofrontal cortex for patients with first-episode schizophrenia: A randomized, double-blind, sham-controlled trial.
     Psychiatry Res. 2023;330:115600.
     PubMed     Abstract available
     
     
     
281. BOGE K, Hallford DJ, Pillny M
     Mindfulness, psychological flexibility and their relationship with psychopathology in persons with schizophrenia-spectrum-disorders and healthy controls - A multicenter cross-sectional study.
     Psychiatry Res. 2023;330:115591.
     PubMed     Abstract available
     
     
     
282. DAZZAN P
     Disentangling psychosis: The challenges of informing precision medicine for what is not a single disorder.
     Psychiatry Res. 2023;330:115596.
     PubMed     Abstract available
     
     
     
283. BERNARDIN F, Gauld C, Martin VP, Laprevote V, et al
     The 68 symptoms of the clinical high risk for psychosis: Low similarity among fourteen screening questionnaires.
     Psychiatry Res. 2023;330:115592.
     PubMed     Abstract available
     
     
     
284. CORNBLATT BA, McFarlane WR, Carrion RE
     Authors' reply to comments on: Recreational cannabis use over time in individuals at clinical high risk for psychosis: Lack of associations with symptom, neurocognitive, functioning, and treatment patterns.
     Psychiatry Res. 2023;330:115594.
     PubMed    
     
     
     
285. KIRSHENBAUM AP, Sofis MJ, Slade M
     Response to recreational cannabis use over time in individuals at clinical high risk for psychosis: lack of associations with symptom, neurocognitive, functioning, and treatment patterns by Carrion et al., 2023.
     Psychiatry Res. 2023;330:115589.
     PubMed    
     
     
     
286. PARK S
     Schizophrenia in the mind, the brain and the body.
     Psychiatry Res. 2023;329:115547.
     PubMed     Abstract available
     
     
     October 2023
287. BIRONG CHEN, Tan XW, Tor PC
     The impact of the number of previous illness episodes on early response to electroconvulsive therapy (ECT) in psychosis, mania, depression, psychotic depression, and catatonia: A naturalistic transdiagnostic analysis.
     Psychiatry Res. 2023;330:115580.
     PubMed     Abstract available
     
     
     
288. KIM HK, Goncalves VF, Husain MI, Muller DJ, et al
     Cross-disorder GWAS meta-analysis of endocannabinoid DNA variations in major depressive disorder, bipolar disorder, attention deficit hyperactivity disorder, autism spectrum disorder, and schizophrenia.
     Psychiatry Res. 2023;330:115563.
     PubMed     Abstract available
     
     
     
289. LIN CH, Huang CJ, Lin TC, Chan HY, et al
     Schizophrenia patients discharged on antipsychotic polypharmacy from a public psychiatric hospital in Taiwan, 2006-2021.
     Psychiatry Res. 2023;330:115575.
     PubMed     Abstract available
     
     
     
290. WANG P, Jiang Y, Hoptman MJ, Li Y, et al
     Structural-functional connectivity deficits of callosal-white matter-cortical circuits in schizophrenia.
     Psychiatry Res. 2023;330:115559.
     PubMed     Abstract available
     
     
     
291. VAN DER TUIN S, Booij SH, Muller MK, van den Berg D, et al
     The added value of daily diary data in 1- and 3-year prediction of psychopathology and psychotic experiences in individuals at risk for psychosis.
     Psychiatry Res. 2023;329:115546.
     PubMed     Abstract available
     
     
     
292. HASSAN L, Eisner E, Berry K, Emsley R, et al
     User engagement in a randomised controlled trial for a digital health intervention for early psychosis (Actissist 2.0 trial).
     Psychiatry Res. 2023;329:115536.
     PubMed     Abstract available
     
     
     
293. SCHLIEF M, Rich N, Rains LS, Baldwin H, et al
     Ethnic differences in receipt of psychological interventions in Early Intervention in Psychosis services in England - a cross-sectional study.
     Psychiatry Res. 2023;330:115529.
     PubMed     Abstract available
     
     
     
294. ZHANG T, Xu L, Wei Y, Tang X, et al
     Duration of untreated prodromal psychosis among individuals with clinical high risk for psychosis.
     Psychiatry Res. 2023;329:115522.
     PubMed     Abstract available
     
     
     
295. KUUSKMAE C, Philips MA, Kilk K, Haring L, et al
     Kynurenine pathway dynamics in patients with schizophrenia spectrum disorders across the disease trajectory.
     Psychiatry Res. 2023;328:115423.
     PubMed     Abstract available
     
     
     September 2023
296. SAMPEDRO A, Pena J, Sanchez P, Ibarretxe-Bilbao N, et al
     Moderators of functional improvement after integrative cognitive remediation in schizophrenia: Toward a personalized treatment approach.
     Psychiatry Res. 2023;329:115495.
     PubMed     Abstract available
     
     
     
297. HUI CLM, Wong CCL, Chan EWT, Suen YN, et al
     COVID-19 exposure and psychosis: A comparison of clinical, functional, and cognitive profiles in remitted patients with psychosis.
     Psychiatry Res. 2023;328:115487.
     PubMed     Abstract available
     
     
     
298. CAMPRODON-BOADAS P, De la Serna E, Plana MT, Flamarique I, et al
     Delusional beliefs in adolescents with anorexia nervosa, obsessive-compulsive disorder, or first-episode psychosis: A comparative study.
     Psychiatry Res. 2023;328:115490.
     PubMed     Abstract available
     
     
     
299. BALDINI V, Stefano RD, Rindi LV, Ahmed AO, et al
     Association between adverse childhood experiences and suicidal behavior in schizophrenia spectrum disorders: A systematic review and meta-analysis.
     Psychiatry Res. 2023;329:115488.
     PubMed     Abstract available
     
     
     
300. GEBREEGZIABHERE Y, Habatmu K, Cella M, Alem A, et al
     Introducing an interview-based cognitive assessment tool for people with Schizophrenia in Ethiopia.
     Psychiatry Res. 2023;328:115474.
     PubMed     Abstract available
     
     
     
301. SANCHEZ-TORRES AM, Garcia de Jalon E, Gil-Berrozpe GJ, Peralta V, et al
     Cognitive intraindividual variability, cognitive impairment and psychosocial functioning in first-episode psychosis patients.
     Psychiatry Res. 2023;328:115473.
     PubMed     Abstract available
     
     
     
302. FORDHAM E, Gao CX, Filia K, O'Donoghue B, et al
     Social disadvantage in early psychosis and its effect on clinical presentation and service access, engagement and use.
     Psychiatry Res. 2023;328:115478.
     PubMed     Abstract available
     
     
     
303. MAURUS I, Roell L, Lembeck M, Papazova I, et al
     Exercise as an add-on treatment in individuals with schizophrenia: Results from a large multicenter randomized controlled trial.
     Psychiatry Res. 2023;328:115480.
     PubMed     Abstract available
     
     
     
304. INCHAUSTI L, Gorostiza I, Gonzalez Torres MA, Oraa R, et al
     The transition to Schizophrenia spectrum disorder from a first psychotic episode that did or did not appear to be induced by substance use.
     Psychiatry Res. 2023;328:115475.
     PubMed     Abstract available
     
     
     
305. FANG X, Gao C, Wu W, Hu X, et al
     The role of the gut microbiome in weight-gain in schizophrenia patients treated with atypical antipsychotics: Evidence based on altered composition and function in a cross-sectional study.
     Psychiatry Res. 2023;328:115463.
     PubMed     Abstract available
     
     
     
306. ZHANG J, Yang Y, Liu T, Shi Z, et al
     Functional connectivity in people at clinical and familial high risk for schizophrenia.
     Psychiatry Res. 2023;328:115464.
     PubMed     Abstract available
     
     
     
307. SMITH ECC, Au E, Pereira S, Sharma E, et al
     Clinical improvement in schizophrenia during antipsychotic treatment in relation to changes in glucose parameters: A systematic review.
     Psychiatry Res. 2023;328:115472.
     PubMed     Abstract available
     
     
     
308. LUCKHOFF HK, Asmal L, Smit R, Phahladira L, et al
     Sex, gender, and outcome in first-episode psychosis: The role of premorbid functioning.
     Psychiatry Res. 2023;328:115460.
     PubMed     Abstract available
     
     
     
309. SEGAL SP, Rimes L, Badran L
     Crime and victimization outcomes following civil rights limits to the use of compulsory treatment.
     Psychiatry Res. 2023;327:115377.
     PubMed     Abstract available
     
     
     
310. JOSHI YB, Gonzalez CE, Molina JL, MacDonald LR, et al
     Mismatch negativity predicts initial auditory-based targeted cognitive training performance in a heterogeneous population across psychiatric disorders.
     Psychiatry Res. 2023;327:115215.
     PubMed     Abstract available
     
     
     
311. XIE Y, Guan M, Wang Z, Ma Z, et al
     Alterations in brain connectivity patterns in schizophrenia patients with auditory verbal hallucinations during low frequency repetitive transcranial magnetic stimulation.
     Psychiatry Res. 2023;328:115457.
     PubMed     Abstract available
     
     
     August 2023
312. CARRION RE, Auther AM, McLaughlin D, Adelsheim S, et al
     Recreational cannabis use over time in individuals at clinical high risk for psychosis: Lack of associations with symptom, neurocognitive, functioning, and treatment patterns.
     Psychiatry Res. 2023;328:115420.
     PubMed     Abstract available
     
     
     
313. JOHANSSON M, Hjarthag F, Helldin L
     Exploring cross-sectional and longitudinal symptomatic remission and subjective quality of life in schizophrenia.
     Psychiatry Res. 2023;328:115421.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum